Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 1/20 | 0.36 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.36 |
| ▸ | ALPL | P05186 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 2/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.34 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.32 |
| ▸ | LIPE | Q05469 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534598 | 0.90 | AAK1 (0.34) | LPLLIPGALPLEGFRAAK1 | |
| SCHEMBL3670014 | 0.83 | ALPL (0.36) | ALPLEGFRAAK1UCHL1 | |
| SCHEMBL30132973 | 0.83 | ALPL (0.36) | ALPLEGFRAAK1UCHL1 | |
| SCHEMBL15393439 | 0.82 | LPL (0.41) | LPLLIPGEGFRCXCR2LIPE | |
| SCHEMBL31441536 | 0.81 | ACACB (0.33) | LPLLIPGAAK1 | |
| SCHEMBL14038064 | 0.81 | EGFR (0.38) | ALPLEGFRAAK1UCHL1LIPE | |
| SCHEMBL30006214 | 0.81 | EGFR (0.38) | ALPLEGFRAAK1UCHL1LIPE | |
| SCHEMBL23658912 | 0.81 | KMT2A (0.40) | ALPLAAK1LIPE | |
| SCHEMBL23658807 | 0.79 | UCHL1 (0.40) | LPLLIPGALPLEGFRAAK1 | |
| SCHEMBL17752336 | 0.79 | LPL (0.39) | LPLLIPGEGFRCXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 101 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CYSTIC FIBROSIS FOUNDATION (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4703359-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Shanghai Simr Biotechnology Co., Ltd. (CN) | 2026-03-04 | — | — | EP | disclosed |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ENLIVEN INC. | 2025-07-24 | — | — | US | disclosed |
| US-20250171427-A1 | THERAPEUTIC COMPOUNDS | SANOFI (FR) | 2025-05-29 | — | — | US | disclosed |
| WO-2025104230-A1 | BENZOXAZOLES AS MODULATORS OF IL-17A | SANOFI (FR) | 2025-05-22 | — | — | WO | disclosed |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ENLIVEN INC. (US) | 2025-03-04 | — | — | US | disclosed |
| WO-2024222712-A1 | IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 上海赛默罗生物科技有限公司 | 2024-10-31 | — | — | WO | disclosed |
| EP-4424311-A2 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | Cystic Fibrosis Foundation (US) | 2024-09-04 | — | — | EP | disclosed |
| EP-3541390-B1 | PYRROLOPYRIMIDINES AS CFTR POTENTIATORS | CYSTIC FIBROSIS FOUND (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | MEDIVIR AB (SE) | 2024-02-22 | — | — | US | disclosed |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | SHIONOGI & CO., LTD. (JP) | 2014-02-13 | — | — | US | disclosed |
| US-20130253194-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2013-09-26 | — | — | US | disclosed |
| WO-2013134228-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2013-09-12 | — | — | WO | disclosed |
| US-8487103-B2 | Quinoline inhibitors of hepatitis C virus polymerase | ROCHE PALO ALTO LLC (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
| US-8026253-B2 | Quinoline inhibitors of HCV polymerase | ROCHE PALO ALTO LLC (US) | 2011-09-27 | — | — | US | disclosed |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | DE VICENTE FIDALGO JAVIER | 2010-12-09 | — | — | US | disclosed |
| EP-2164840-A2 | MODULATORS OF CFTR | Vertex Pharmaceuticals Incorporated (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008141119-A2 | MODULATORS OF CFTR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240059689-A1 | PURINE DERIVATIVES AS ANTICANCER AGENTS | RRM2, TYMP, PNP | LPL 4447/4885LIPG 4853/4885ALPL 3029/4885 |
| US-20100311760-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, XDH, GTF3C4 | LPL 3007/4885LIPG 2768/4885ALPL 4286/4885 |
| US-20140045830-A1 | CYCLIC UREA- OR LACTAM-SUBSTITUTED QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF | QPCT, UBXN1, NQO2 | LPL 3412/4885LIPG 2140/4885ALPL 2479/4885 |
| US-20250236621-A1 | 5- AND 6-AZAINDOLE COMPOUNDS FOR INHIBITION OF BCR-ABL TYROSINE KINASES | ABL1, ABL2, BCR | LPL 2822/4885LIPG 1785/4885ALPL 3397/4885 |
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, IRF3 | LPL 3929/4885LIPG 3617/4885ALPL 4622/4885 |
| US-20130253194-A1 | PYRAZOLO[1,5-a]PYRIMIDINE-BASED COMPOUNDS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | TPX2, MAP3K1, IRAK1 | LPL 3039/4885LIPG 1854/4885ALPL 4735/4885 |
| US-12612409-B2 | Pyrrolopyrimidines as CFTR potentiators | CFTR, CLCN2, SLC26A3 | LPL 2293/4885LIPG 3266/4885ALPL 2976/4885 |
| US-12240846-B2 | 5- and 6-azaindole compounds for inhibition of Bcr-Abl tyrosine kinases | ABL1, ABL2, BCR | LPL 2822/4885LIPG 1785/4885ALPL 3397/4885 |
| US-20250171427-A1 | THERAPEUTIC COMPOUNDS | IL17A, IL2, IL36G | LPL 868/4885LIPG 419/4885ALPL 4626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.